SO vs. EDIT

Last updated Jun 13, 2026

SO (The Southern Company) and EDIT (Editas Medicine, Inc.) are both stocks. SO operates in Utilities - Regulated Electric (Utilities), while EDIT operates in Biotechnology (Healthcare). Over the past 10 years, SO returned 10.77%/yr vs -22.22%/yr for EDIT. At a 0.01 correlation, their price movements are largely independent.

Performance

SO vs. EDIT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in The Southern Company (SO) and Editas Medicine, Inc. (EDIT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SO achieves a 10.02% return, which is significantly lower than EDIT's 21.95% return. Over the past 10 years, SO has outperformed EDIT with an annualized return of 10.77%, while EDIT has yielded a comparatively lower -22.22% annualized return.

SO

• 1D: 1.22%
• 1M: 2.86%
• YTD: 10.02%
• 6M: 13.62%
• 1Y: 7.91%
• 3Y*: 14.19%
• 5Y*: 12.20%
• 10Y*: 10.77%

EDIT

• 1D: 2.46%
• 1M: -4.58%
• YTD: 21.95%
• 6M: -1.19%
• 1Y: 26.90%
• 3Y*: -39.82%
• 5Y*: -41.79%
• 10Y*: -22.22%

*Multi-year figures are annualized to reflect compound growth (CAGR)

SO vs. EDIT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SO The Southern Company	10.02%	9.47%	21.72%	2.21%	8.24%	16.34%	0.63%	51.65%	-3.75%	2.42%
EDIT Editas Medicine, Inc.	21.95%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%

Correlation

The correlation between SO and EDIT is 0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.00
Correlation (3Y) Calculated over the trailing 3-year period	0.04
Correlation (5Y) Calculated over the trailing 5-year period	0.06
Correlation (10Y) Calculated over the trailing 10-year period	0.02
Correlation (All Time) Calculated using the full available price history since Feb 3, 2016	0.01

Fundamentals

Market Cap SO : $106.03B EDIT : $244.70M
EPS SO : $3.92 EDIT : -$1.21
PS Ratio SO : 3.47 EDIT : 6.29
PB Ratio SO : 2.86 EDIT : 55.51
Total Revenue (TTM) SO : $30.17B EDIT : $35.86M
Gross Profit (TTM) SO : $13.01B EDIT : $35.86M
EBITDA (TTM) SO : $14.44B EDIT : -$76.66M

Return for Risk

SO vs. EDIT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SO

SO Risk / Return Rank: 54
SO Sharpe Ratio Rank: 60
SO Sortino Ratio Rank: 52
SO Omega Ratio Rank: 50
SO Calmar Ratio Rank: 55
SO Martin Ratio Rank: 56

EDIT

EDIT Risk / Return Rank: 51
EDIT Sharpe Ratio Rank: 48
EDIT Sortino Ratio Rank: 56
EDIT Omega Ratio Rank: 53
EDIT Calmar Ratio Rank: 49
EDIT Martin Ratio Rank: 48

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SO vs. EDIT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for The Southern Company (SO) and Editas Medicine, Inc. (EDIT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	SO	EDIT	Difference
Sharpe ratio: Return per unit of total volatility	0.49	0.16	+0.33
Sortino ratio: Return per unit of downside risk	0.81	0.98	-0.17
Omega ratio: Gain probability vs. loss probability	1.10	1.11	-0.02
Calmar ratio: Return relative to maximum drawdown	0.53	0.25	+0.28
Martin ratio: Return relative to average drawdown	1.24	0.43	+0.81

SO vs. EDIT - Sharpe Ratio Comparison

The current SO Sharpe Ratio is 0.49, which is higher than the EDIT Sharpe Ratio of 0.16. The chart below compares the historical Sharpe Ratios of SO and EDIT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

SO vs. EDIT - Drawdown Comparison

The maximum SO drawdown since its inception was -38.43%, smaller than the maximum EDIT drawdown of -98.92%. Use the drawdown chart below to compare losses from any high point for SO and EDIT.

Drawdown Indicators

	SO	EDIT	Difference
Max Drawdown Largest peak-to-trough decline	-38.43%	-98.92%	+60.49%
Max Drawdown (1Y) Largest decline over 1 year	-14.99%	-59.88%	+44.89%
Max Drawdown (3Y) Largest decline over 3 years	-14.99%	-91.18%	+76.19%
Max Drawdown (5Y) Largest decline over 5 years	-23.28%	-98.66%	+75.38%
Max Drawdown (10Y) Largest decline over 10 years	-38.43%	-98.92%	+60.49%
Current Drawdown Current decline from peak	-3.95%	-97.24%	+93.29%
Average Drawdown Average peak-to-trough decline	-6.87%	-62.63%	+55.76%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.39%	34.03%	-27.64%

Volatility

SO vs. EDIT - Volatility Comparison

The current volatility for The Southern Company (SO) is 6.03%, while Editas Medicine, Inc. (EDIT) has a volatility of 32.34%. This indicates that SO experiences smaller price fluctuations and is considered to be less risky than EDIT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SO	EDIT	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.03%	32.34%	-26.31%
Volatility (6M) Calculated over the trailing 6-month period	13.07%	61.63%	-48.56%
Volatility (1Y) Calculated over the trailing 1-year period	16.21%	94.75%	-78.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	18.67%	94.12%	-75.45%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	21.96%	83.80%	-61.84%

Dividends

SO vs. EDIT - Dividend Comparison

SO's dividend yield for the trailing twelve months is around 3.60%, while EDIT has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
EDIT Editas Medicine, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SO The Southern Company	3.60%	3.37%	3.47%	3.96%	3.78%	3.82%	4.13%	3.86%	5.42%	4.78%	4.52%	4.60%

Financials

Frequently Asked Questions

Can I hold both SO and EDIT in my portfolio?

SO and EDIT have a correlation of 0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SO or EDIT?

EDIT has higher volatility (32.34%) compared to SO (6.03%). In terms of maximum drawdown, SO dropped -38.43% vs EDIT's -98.92%.

Which has better risk-adjusted returns?

SO currently has the higher Sharpe Ratio (0.49 vs 0.16), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.